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Abstract
Background: To develop a novel therapeutic strategy for human pancreatic cancer using a
midkine promoter-based conditionally replicating adenovirus.
Methods: We examined midkine mRNA expression and midkine protein expression by seven
human pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, MIAPaCa-2, PANC-1, and
Suit-2), as well as by non-cancerous pancreatic tissue and pancreatic cancers. Midkine promoter
activity was measured in cancer cell lines by the dual luciferase reporter assay. Adenoviral
transduction efficiency was assessed by fluorescent staining of cancer cell lines using adenovirus
type 5 containing the green fluorescent protein gene (Ad5GFP). Replication of adenovirus type 5
containing the 0.6 kb midkne promoter (Ad5MK) was assessed by the detection of E1 protein in
cancer cell lines. The cytotoxicity of Ad5MK for cancer cells was evaluated from the extent of
growth inhibition after viral infection. Infection and replication were also assessed in nude mice
with subcutaneous Suit-2 tumors by intratumoral injection of Ad5MK, Ad5GFP, or vehicle. E1a
mRNA expression in the treated tumors and expression of the replication-specific adenoviral
hexon protein were evaluated. Finally, the anti-tumor activity of Ad5MK against intraperitoneal
xenografts of Suit-2 pancreatic cancer cells was examined after intraperitoneal injection of the
virus.
Results: Both midkine mRNA expression and midkine protein expression were strong in AsPC-1
and CFPAC-1 cell liens, moderate in BxPC-3, HPAC, and Suit-2 cell lines, and weak in PANC-1 and
MIAPaCa-2 cell lines. Expression of midkine mRNA was significantly stronger in pancreatic cancers
than in non-cancerous pancreatic tissues. The relative luciferase activity mediated by the 0.6 kb
midkne fragment in AsPC-1, PANC-1, and Suit-2 cell lines was approximately 6 to 20 times greater
than that in midkne-negative MIAPaCa-2 cell lines. Pancreatic cancer cell lines exhibited a
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heterogeneous adenoviral transduction profile. E1A expression was higher in cell lines with strong
midkine expression than in cell lines with weak midkine expression. Ad5MK showed much greater
cytotoxicity for midkine-expressing Suit-2 and PANC-1 cell lines than for midkine-negative
MIAPaCa-2 cell lines. In the Suit-2 subcutaneous xenograft model, expression of E1A was detected
in Ad5MK-treated tumors, but not in untreated and Ad5GFP-treated tumors. In the Suit-2
intraperitoneal xenograft model, the Ad5MK group survived for significantly longer than the
Ad5GFP, PBS, and untreated groups.
Conclusion: Ad5MK has an anti-tumor effect against human pancreatic cancer cell lines that
express midkine mRNA. Midkine promoter-based conditionally replicative adenovirus might be a
promising new gene therapy for pancreatic cancer.
Background
Pancreatic cancer is one of the most lethal malignant
tumors, and it was estimated that approximately 200,000
people died of this cancer worldwide in the year 2000 [1].
It is the fifth leading cause of cancer death in Japan and
the fourth in the United States [2]. Unfortunately, the
pancreas is located at an inaccessible site within the abdo-
men, making the diagnosis of pancreatic cancer more dif-
ficult than that of other digestive tract cancers. Therefore,
most patients with pancreatic cancer are diagnosed late
after progression of their disease. Furthermore, pancreatic
cancer frequently infiltrates neighboring tissues or vessels
at an early stage, leading to a poor prognosis.
In the United States, the 1-year and 5-year survival rates of
patients with pancreatic cancer are less than 25% and 5%,
respectively [3]. At present, surgical resection provides the
only chance of cure for these patients, but it has been
reported that about 90% of patients do not undergo pan-
creatic resection and 58% are only given palliative treat-
ment [4]. Moreover, recurrence after surgical resection is
very common. We do not have any effective nonsurgical
treatments for pancreatic cancer, because it shows strong
resistance to the currently available chemotherapy and
radiotherapy protocols [5]. In order to improve the clini-
cal outcome, new modalities for the treatment of this dis-
ease are required.
Gene therapy using oncolytic viruses is one of the
approaches that should be considered. The strategy of this
therapy is to exploits the lytic property of virus replication
to kill tumor cells. Recent knowledge of molecular biol-
ogy makes it possible to modify viruses to target specific
molecules or signal transduction pathways in cancer cells.
Oncolytic viruses which are developed to be able to infect
and replicate selectively in malignant tumor cells can
spread and destroy malignant tumors without adverse
effects in normal tissues.
To achieve tumor-selective viral replication, one approach
has been the replacement of endogenous viral sequences
with a tissue- or tumor-specific promoter. A number of
tumor promoter genes such as α-fetoprotein [6], carci-
noembryonic antigen [7], erbB-2 [8]and prostate-specific
antigen [9,10] have been used to restrict the expression of
suicide genes both in vitro and in vivo.
Midkine is a heparin-binding growth factor that is
induced by retinoic acid in embryonal carcinoma cells,
and it may be another candidate for this purpose [11]. The
biological roles of midkine are diverse and it is closely
linked to neural development [12,13] as well as to the
pathogenesis of neurodegenerative diseases. At the same
time, midkine is involved in the development of cancer
because of its mitogenic effect [14], promotion of angio-
genesis [15], anti-apoptotic activity [16], fibrinolytic activ-
ity [17], and transforming activity [18].
Midkine expression is increased in a number of malignant
tumors, including esophageal, stomach, colon, hepatocel-
lular, breast and pancreatic carcinoma, when compared
with the level of expression in adjacent non-cancerous tis-
sues [19-22]. In contrast, the expression of midkine in
normal human tissues is quite limited, with moderate
expression in the kidneys and weak expression in the
lungs, colon, and thyroid gland [19,20,23].
On this basis, the midkine promoter could be a potential
candidate for use in suicide gene therapy. Here, we dem-
onstrate that an adenovirus vector encoding the essential
adenoviral E1A gene under the control of 0.6 kb midkine
promoter showed specific replication in midkine-express-
ing pancreatic cancer cell lines and not in non-midkine-
expressing cells, and that Ad5MK selectively prevented
tumor growth both in vitro and in vivo.
Methods
Cell culture and tumor samples
Seven human pancreatic cancer cell lines were used. AsPC-
1, BxPC-3, CFPAC-1, HPAC, MIAPaCa-2, and PANC-1
cells were obtained from the American Type Culture Col-
lection (Rockville, MD), and were maintained in the
medium recommended by the ATCC at 37°C in a humid-
ified atmosphere of 5% CO2. Suit-2 cells were kindly pro-Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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vided by Dr. Tomoda (National Kyushu Cancer Center,
Fukuoka, Japan), and were cultured in DMEM (Gibco-
BRL, Grand Island, NY) with 10% fetal bovine serum
(FBS) (ICN Biomedicals, Aurora, Ohio). Human embry-
onic kidney (HEK) 293 cells were purchased from RIKEN
Bioresourse Center (Tukuba, Ibaragi, Japan). Each culture
medium contained 100 units/ml of penicillin and 0.1 mg/
ml of streptomycin (Gibco-BRL).
Pancreatic cancer tissues were obtained from 22 patients
who underwent pancreatectomy for ductal carcinoma at
our Department. Other pancreatic malignancies were
excluded, such as intraductal papillary mucinous adeno-
carcinoma, acinar cell carcinoma, and endocrine tumors.
Informed consent was obtained from each patient accord-
ing to our Institutional guidelines. A resected specimen
was immediately examined by inspection and palpitation
at the operation room. A part of malignant or normal tis-
sues considered was cut by surgical knife and it was
divided two pieces. One for the tissue samples to extract
RNA was immediately frozen in liquid nitrogen and
stored at -80°C, the other was fixed in 10% formalin solu-
tion to make a paraffin block and performed with HE
staining to evaluate pathologically.
Antibodies
Rabbit polyclonal anti-midkine antibody was kindly pro-
vided by Dr. Kadomatsu (Nagoya University School of
Medicine, Nagoya, Japan). The following antibodies were
purchased; mouse monoclonal anti-E1A (Ad2/Ad5) anti-
body (clone M73 #05-599) from Upstate Biotechnology
(Lake Placid, NY), goat anti-mouse IgG (#62-6500) and
HRP-goat anti-mouse IgG (#81-6520) from Zymed Labo-
ratories (South San Francisco, CA), and mouse mono-
clonal anti-β-actin (clone AC-15 #A-5441) from Sigma
(St. Louis, MO). Anti-adenoviral hexon protein antibody
was included in the Adeno-X rapid titer kit (BD Bio-
sciences Clontech, Palo Alto, CA).
RNA extraction and reverse transcription-polymerase 
chain reaction (RT-PCR)
Total cellular RNA was prepared using TRIZOL Reagent
(Life Technologies, Rockville, MD) and cDNA was
obtained from 1 μg of total RNA by the random primer
method with a First-Strand cDNA Synthesis kit (Pharma-
cia Biotech, North Peapack, NJ) according to the manufac-
turer's instructions. Five microliters of first-strand cDNA
solution was subjected to the polymerase chain reaction
(PCR) with synthetic oligonucleotide primers (NIPPON
EGT, Toyama, Japan). For RT-PCR analysis of human ade-
novirus type 5 E1A, a pair of primers (5'-ATGAGACATAT-
TATCTGCCACGG-3'/5'-
TAGACAAACATGCCACAGGTCC-3') was used and PCR
was done for 35 cycles at 54°C, yielding a product of 551
base pairs. The reproducibility of the technique and qual-
ity of the total RNA were confirmed by amplifying β-actin
as well (primers: 5'-GGCATCGTGATGGACTCCG-3'/5'-
GCTGGAAGGTGGACAGCGA-3'; product: 613 base
pairs).
Quantitative RT-PCR
To assess midkine gene expression, we used quantitative
real-time RT-PCR analysis based on the TaqMan fluores-
cence method, which employs a dual-labeled non-extend-
able oligonucleotide hydrolysis (TaqMan) probe in
addition to the two amplification primers. The probe con-
tains 6-carboxy-fluorescein (FAM) as a fluorescent
reporter dye, and 6-carboxytetramethyl-rhodamine
(TAMRA) as a quencher for its emission spectrum. During
the extension phase of PCR, the probe hybridizes to the
target sequence and is then cleaved by the 5' to 3' exonu-
clease activity of Taq polymerase. The increase in the fluo-
rescence of the reporter is proportional to the amount of
specific PCR products, providing highly accurate and
reproducible quantification. The level of reporter dye flu-
orescence is assessed with an automated sequence detec-
tor combined with analysis software (ABI Prizm 7700
Sequence Detection System; PE Applied Biosystems, Fos-
ter City, CA). Reaction conditions were set according to
the manufacturer's protocol. The following primers and
TaqMan probe were used for analysis. The midkine-spe-
cific primers were 5'-CGACTGCAAGTACAAGTTTGA-
GAAC-3' (upstream primer) and 5'-
TCTCCTGGCACTGAGCATTG-3' (downstream primer),
while 5' (FAM)-AAGGCACCCTGAAGAAGGCGCG-
(TAMRA) 3' was the TaqMan probe.
The PCR parameters were 95°C for 10 min (for activation
of Taq-Polymerase), followed by 40 cycles of 95°C for 15
s and 60°C for 1 min. Amplification of β-actin for quality
control and normalization was done with the TaqMan β-
actin Control Reagent kit (PE Applied Biosystems), which
utilizes standard TaqMan probe chemistry.
Western blot analysis
Cells were lysed in RIPA buffer containing 50 mM HEPES
(pH 7.0), 250 mM NaCl, 0.1% Nonidet P-40, 1 mM phe-
nylmethylsulfonylfluoride (PMSF), and 20 μg/ml gabex-
ate mesilate, and were incubated on ice for 10 minutes.
Then the lysate was sonicated for 10 sec. Total extracts
were cleaned by centrifugation at 15,000 rpm for 10 min
at 4°C and the supernatants were collected. The protein
concentration was measured with the BCA protein assay
reagent (Pierce, Rockford, IL). Lysates were resuspended
in one volume of gel loading buffer, which contained 50
mM Tris-Hcl (pH 6.7), 4% SDS, 0.02% bromophenol
blue, 20% glycerol, and 4% 2-mercaptoethanol, and then
were heated at 95°C for 5 min. The extracted protein was
subjected to Western blotting. In brief, 50 μg aliquots of
protein were size-fractionated in a single dimension byJournal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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SDS-PAGE (6–10% gels) and transblotted to 0.45 μm pol-
yvinylidine difluoride membranes (IPVH304F0, Milli-
pore, Billerica, MA) with a semi-dry electroblotting
apparatus (Bio-Rad, Richmond, CA).
The blots were then washed three times in TBS with 0.1%
Tween-20 (TBST) and incubated for 1 hour at room tem-
perature in blocking buffer (Block Ace, Dainipponsei-
yaku, Osaka, Japan). Subsequently, the blots were
incubated with an appropriate primary antibody for 1 h at
room temperature or overnight at 4°C. Excess antibody
was removed by washing the membrane with TBST three
times for 10 min each. Then the membrane was incubated
with a horseradish peroxidase-conjugated secondary anti-
body for 1 h at room temperature, followed by an addi-
tion of TBST. Reaction products were detected with the
enhanced chemiluminescence system (Amersham, Buck-
inghamshire, United Kingdom). The membranes were
treated with chemiluminescence reagents according to the
manufacturer's protocol, and were exposed to X-ray films
for 5–120 sec.
Dual luciferase assay
We prepared the midkne 0.6-luc vector, in which the 609-
base pair genomic DNA fragment of the midkne gene was
cloned into the pGL2-basic vector (Promega, Madison,
WI) and the firefly luciferase gene was included without a
promoter sequence[24].
The transcripitional activity of a number of pancreatic
cancer cell lines was measured with this dual luciferase
reporter assay system (Promega, Madison, WI). Midkine
0.6-luc and a control vector (the renilla luciferase gene
fused with the HSV-TK promoter (pRL-TK, Promega, Mad-
ison, WI) at a molar ratio of 10:1) were transfected
together into target cells using Lipofectamine 2000 (Invit-
rogen, Carlsbad, CA). The cells were lysed after 2 days and
luciferase activity was measured according to the manu-
facturer's protocol. The relative firefly luciferase activity of
each cell lysate was calculated from the level of lumines-
cence.
Adenoviruses and adenoviral transduction analysis
We prepared recombinant adenovirus type 5 containing
the 0.6 kb midkne promoter (Ad5MK) for midkne-regu-
lated expression of E1A[24]. Type 5, E1A-deleted, replica-
tion-defective adenovirus containing the green
fluorescent protein gene (Ad5GFP) was constructed using
AdEasy XL Adenoviral Vector System (Stratagene, La Jolla,
CA) according to the manufacturer's protocol. Adenovi-
ruses were propagated in HEK 293 cells, purified by two
rounds of cesium chloride density centrifugation, dia-
lyzed, and stored at -70°C. Viral titers were determined
with an Adeno-X Rapid Titer Kit (BD Biosciences Clon-
tech, Palo Alto, CA).
To assess the efficiency of adenoviral transduction in
human pancreatic cancer cells, we performed fluorescent
staining using Ad5GFP. Pancreatic cancer cells were
seeded onto coverslips and infected with at recombinant
adenovirus at various multiplicities of infection (MOIs).
After 48 hours, coverslips were mounted on the glass
slides with Vectashield mounting medium (Vector Labol-
atories, Burlingame, CA), and the cells were examined
under a fluorescence microscope (Olympus, Tokyo,
Japan).
Assessment of adenoviral replication
First, cells were infected with Ad5MK at various MOIs for
1 h and then the virus was removed. The infected cells
were lysed in RIPA buffer to extract proteins after culture
for 48 h. The proteins were subjected to SDS-PAGE and
expression of E1A protein was analyzed by Western blot-
ting. Next, cells were infected with Ad5MK at 1 MOI for 1
h and the medium was then refreshed. After the cells were
cultured for 2 days, the cell lysate was prepared with three
cycles of freezing and thawing.
HEK293 cells were infected with serially diluted cell
lysates or tissue lysates. After 48 hr, the cells were stained
with anti-adenoviral hexon protein antibody by using an
Adeno-X rapid titer kit (BD Biosciences Clontech, Palo
Alto, CA).
In vitro cytotoxicity test
Pancreatic cancer cells were plated into 12-well plates in
triplicate at a density of 1.0 × 104 cells/well. After 24- to 36
h of culture, cells were infected with Ad5GFP or Ad5MK at
various MOIs for 1 h, and the infecting medium was
replaced with complete medium. After 1, 3 and 5 days, the
number of viable cells was counted using a cell counter
(Coulter Z1, Beckman-Coulter, Fullerton, CA).
Animal study
The animal study was performed in accordance with the
guidelines for animal experiments of the Institute of Lab-
oratory Animals at Kyoto University. Six-week-old male
BALB/c nude mice were purchased from CLEA Japan
(Tokyo, Japan). First, the mice were subcutaneously inoc-
ulated with Suit-2 cells (2 × 106/ml) in 100 μl of Hank's
balanced salt solution (HBSS) (Gibco-BRL) containing
20% matrigel (BD Biosciences, Bedford, MA). When the
tumors reached about 10 mm in diameter, Ad5GFP or
Ad5MK (2 × 109 PFU, 0.1 ml/mouse) was injected intratu-
morally. The mice were sacrificed at 3 or 7 days after ade-
noviral injection to extract RNA and lysates from the
tumors. RT-PCR analysis of human adenovirus type 5 E1A
and staining with anti-adenoviral hexon antibody were
performed to assess the replication of adenoviruses in vivo.Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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Next, Suit-2 cells (2 × 106/ml) in 500 μl of sterile PBS were
inoculated into the peritoneal cavity of BALB/c nude mice
to create a peritoneal dissemination xenograft model. The
mice were divided into the following 4 groups: (1) an
Ad5MK group, (2) an Ad5GFP group, (3) a PBS group,
and (4) an untreated group. Ad5MK (2 × 109 PFU, 0.5 ml/
mouse), Ad5GFP (2 × 109 PFU, 0.5 ml/mouse) or PBS (0.5
ml/mouse) was administered intraperitoneally at 4 days
after the injection of Suit-2 cells. Survival was measured
from the start of treatment.
Statistical analysis
Quantitative data are presented as the mean ± SEM. Each
in vitro experiment was performed independently at least
three times. To compare mRNA levels in pancreatic tissue
samples, Wilcoxon's rank sum test was used. Survival rates
were calculated by the Kaplan-Meier method, and differ-
ences between groups were evaluated with the log-rank
test and Wilcoxon's test. Statistical analysis was done by
using JMP statistical software and statistical significance
was considered to be present at p < 0.05.
Results
Midkine expression by human pancreatic cancer cell lines
We examined the expression of midkine mRNA in seven
human pancreatic cancer cell lines by TaqMan PCR (Table
1). Midkine mRNA expression was strong in AsPC-1 and
CFPAC-1 cells, but it was weak in MIAPaCa-2 cells.
Next, midkine protein expression was assessed by Western
blot analysis (Figure 1A). AsPC-1 and CFPAC-1 cells
showed strong expression of midkine protein, whereas
BxPC-3, HPAC and Suit-2 cells showed moderate expres-
sion. In contrast, expression by PANC-1 cells was weak
and MIAPaCa-2 cells showed no midkine band. The
extent of midkine protein expression was in parallel to
that of midkine mRNA expression. In the following exper-
iments, we therefore designated the MIAPaCa-2 cell line
as midkine-negative.
Midkine expression in human pancreatic cancer
We assessed the expression of midkine mRNA in 22 pan-
creatic cancer samples and 18 adjacent non-cancerous
pancreatic tissue samples by TaqMan PCR (Figure 1B).
The midkine mRNA/β-actin mRNA ratio of pancreatic
cancer and non-cancerous pancreatic tissue was 0.60 ±
0.55 and 0.22 ± 0.13, respectively. Expression of midkine
mRNA was significantly stronger in pancreatic cancer than
in non-cancerous tissue (p < 0.001).
Transcriptional activity of the midkine promoter in human 
pancreatic cancer cells
We investigated the transcriptional activity of the midkine
promoter by the dual luciferase reporter assay in AsPC-1,
CFPAC-1, MIAPaCa-2, PANC-1, and Suit-2 cells (Table 2).
This assay showed that the relative luciferase activity
mediated by the 0.6 kb midkne fragment in AsPC-1,
PANC-1, and Suit-2 cells was approximately 6 to 20 times
greater than that in midkne-negative MIAPaCa-2 cells.
Transcriptional activity in MIAPaCa-2 cells was extremly
low. The transcriptional activity in each of the cell lines
was usually correlated with the expression of midkne,
although CFPAC-1 cells showed low transcriptional activ-
ity and high midkne expression.
Sensitivity of human pancreatic cancer cell lines to 
adenovirus infection
We examined the induction of Ad5GFP in human pancre-
atic cancer cells (Figure 2). Cells were infected with
Ad5GFP (1, 10, or 25 MOI) at 16 to 18 h after seeding.
After 48 h, GFP-expressing cells were detected by fluores-
cence microscopy. We found that pancreatic cancer cells
exhibited a heterogeneous adenoviral transduction pro-
file. Many of the CFPAC-1 and Suit-2 cells infected at an
MOI of 25 expressed GFP, whereas AsPC-1 cells showed
far lower adenoviral transduction efficiency. We also
found that the number of GFP-expressing cells increased
in an MOI-dependent manner.
Ad5MK shows specific replication and infectivity for 
human pancreatic cancer cell lines
Since the adenoviral infection cycle is completed within
24 h, E1A expression by infected cells after 48 h reflects
viral replication. Therefore, to determine the specificity of
Ad5MK replication, we used pancreatic cancer cell lines
with different levels of midkine expression and then
examined E1A expression by Western blotting (Figure
3A). We found that viral replication was dependent on the
MOI of infection.
Next, we examined the infectivity of Ad5MK prepared
from pancreatic cell line in HEK293 cells by using an anti-
adenoviral hexon antibody (Figure 3B). Stained HEK293
cells were found after infection with preparations from
midkine-positive cells (PANC-1, Suit-2, AsPC-1, and
Table 1: Expression of midkine mRNA in human pancreatic 
cancer cells.
Cell line Midkine mRNA/β-actin mRNA
AsPC-1 1.19 ± 0.04
BxPC-3 0.37 ± 0.01
CFPAC-1 1.42 ± 0.02
HPAC 0.31 ± 0.01
MIAPaCa-2 0.001 ± 0.0004
PANC-1 0.02 ± 0.001
Suit-2 0.13 ± 0.003
Data are expressed as the mean ± SEM.Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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Midkine protein expression by human pancreatic cancer cell lines and human pancreatic cancer tissues Figure 1
Midkine protein expression by human pancreatic cancer cell lines and human pancreatic cancer tissues. (A) 
Midkine protein expression by human pancreatic cancer cell lines. AsPC-1 and CFPAC-1 cells showed strong expression of 
midkine protein, whereas BxPC-3, HPAC, and Suit-2 cells showed moderate expression. In contrast, expression by PANC-1 
cells was low and MIAPaCa-2 cells showed no detectable midkine band. (B) Midkine mRNA expression in non-cancerous pan-
creatic tissues and human pancreatic cancers. Expression of midkine mRNA in the pancreatic cancers was significantly stronger 
than in the non-cancerous pancreatic tissues (p < 0.001).Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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CFPAC-1), whereas there were no stained cells after infec-
tion with a preparation from midkine-negative MIAPaCa-
2 cells.
Specific cell killing effect of Ad5MK in vitro
We subsequently examined the ability of Ad5MK to kill
pancreatic cancer cells (Figure 4). The number of viable
cells was counted by using a Coulter counter. Ad5MK
showed a much stronger-killing effect against Suit-2 and
PANC-1 cells that have moderate and weak midkine
expression, respectively, compared with its effect on mid-
kine-negative MIAPaCa-2 cells.
On the other hand, moderate cell-killing effect against
CFPAC-1 cells was found in 10 MOI of Ad5MK. CFPAC-1
cells had high midkine expression and moderate effi-
ciency of adenoviral transduction. Transcriptional activity
of midkine promoter in CFPAC-1 cells was low, but it was
higher compared to that of MIAPaCa-2 cells. This may be
the reason why growth suppression of CFPAC-1 cells was
observed by 10 MOI of Ad5MK. In contrast, Ad5MK had
no effect on AsPC-1 cells as far as the designated condi-
tions, although these cells showed strong midkine expres-
sion. This finding may have reflected low efficiency of
adenoviral transduction. Ad5GFP had no influence on the
growth of any of the cells in this assay compared with nor-
mal control cells (data not shown).
Adenoviral replication and anti-tumor effect of Ad5MK in 
vivo
We assessed adenoviral replication in vivo by using a Suit-
2 subcutaneous xenograft model of pancreatic cancer.
Table 2: Transcriptional activity of MK promoter in human 
pancreatic cancer cells.
Cell lines Relative luciferase activity
AsPC-1 0.57 ± 0.09
CFPAC-1 0.06 ± 0.01
MIAPaCa-2 0.03 ± 0.01
PANC-1 0.16 ± 0.02
Suit-2 0.29 ± 0.01
Relative luciferase activity was defined as firefly luciferase activity per 
renilla luciferase activity in cancer cells. Data are expressed as the 
mean ± SEM.
Sensitivity of human pancreatic cancer cell lines to adenovirus infection Figure 2
Sensitivity of human pancreatic cancer cell lines to adenovirus infection. Pancreatic cancer cells were infected with 
Ad5GFP (1, 10 or 25 MOI) at 16 to 18 h after seeding. After 48 h, GFP-expressing cells were detected by fluorescence micro-
scopy. (Original magnification ×100).Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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RNA and tumor lysates were obtained from the subcuta-
neous xenografts after injection of adenoviruses. RT-PCR
analysis for human adenovirus type 5 E1A showed that
E1A expression could be detected in the Ad5MK groups
(Figure 5A). On the other hand, no band was seen in the
untreated and Ad5GFP groups. After staining with anti-
adenoviral hexon antibody, positive cells were only found
in the Ad5MK groups, whereas there were no positive cells
in the untreated and Ad5GFP groups (Figure 5B).
Finally, we assessed the anti-tumor effect in a Suit-2 intra-
peritoneal xenograft model after the intraperitoneal injec-
Replication specificity and infectivity of Ad5MK for human pancreatic cancer cell lines Figure 3
Replication specificity and infectivity of Ad5MK for human pancreatic cancer cell lines. (A) E1A protein expression 
by pancreatic cancer cells. Pancreatic cancer cell lines were infected with Ad5MK showing different levels of midkine expres-
sion, Ad5GFP alone, or the vehicle. (B) Adenoviral hexon staining. HEK293 cells were treated with preparations of Ad5MK-
infected pancreatic cancer cells. After 48 hr, HEK293 cells were stained with anti-adenoviral hexon antibody. (Original magnifi-
cation ×100)Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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tion of Ad5MK (Figure 6). Following the inoculation of 2
× 106/ml Suit-2 cells into the peritoneal cavity of nude
mice, 2 × 109 PFU of Ad5MK or Ad5GFP, or 500 μl of PBS,
was administered intraperitoneally. In this intraperitoneal
xenograft model, our preliminary study revealed that
untreated mice died of peritoneal dissemination with
bloody ascites after approximately 2 to 3 weeks. Almost all
of the mice in the untreated, PBS, and Ad5GFP groups
died within 35 days, whereas almost all of the mice in the
Ad5MK group survived for more than 50 days. There was
a statistically significant difference of the survival time
between the Ad5MK group and the other group.
Discussion
Conditionally replicative adenoviruses, which show
tumor-specific replication and oncolysis, are a promising
new treatment modality for malignancies resistant to con-
ventional therapies [25,26]. In this study, we demon-
strated a possible strategy for pancreatic cancer based on
Ad5MK replication-competent adenovirus. Midkine
expression is increased in various human tumors, includ-
ing gastrointestinal cancers [19-22]. We showed that most
human pancreatic cancer cell lines (6 out of 7 lines tested)
express midkine to some extent and that the level of mid-
kine mRNA expression in pancreatic cancer tissues is sig-
nificantly higher than in non-cancerous pancreatic tissues.
These findings suggested that the midkine promoter may
be a potential candidate for safe suicide gene therapy tar-
geting pancreatic cancer.
We next examined the promoter activity of midkine in a
dual luciferase reporter assay. A 2.3-kb fragment from the
5' region of the midkine gene contains the elements
responsible for promoter activity [27]. Within this 2.3-kb
In vitro cytotoxicity of Ad5MK Figure 4
In vitro cytotoxicity of Ad5MK. Pancreatic cancer cells were plated in triplicate in 12-well plates at 1.0 × 104 cells/well. 
After 24 to 36 h, the cells were infected with Ad5GFP or Ad5MK at various MOIs. After 1, 3, and 5 days, the number of viable 
cells was counted.Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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Replication of adenovirus in a Suit-2 subcutaneous xenograft model of pancreatic cancer Figure 5
Replication of adenovirus in a Suit-2 subcutaneous xenograft model of pancreatic cancer.(A) Human adenovirus 
type 5 E1A expression. RNA was extracted from subcutaneous tumors after injection of adenoviruses. Expression of E1A was 
analyzed by RT-PCR. (B) Adenoviral hexon staining. HEK293 cells were infected with Ad5MK prepared from subcutaneous 
xenografts after injection of adenoviruses. After 48 hr, HEK293 cells were stained with anti-adenoviral hexon antibody. Posi-
tive cells were only found in the Ad5MK groups, whereas there were no positive cells in the untreated and Ad5GFP groups. 
(Original magnification ×100)Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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fragment, Yoshida et al. have demonstrated the presence
of a cis-element with strong promoter activity located at
the -559/50 region using the CAT assay, and they also
reported that its midkine promoter activity in tumor cells
was comparable to that of the SV40 early promoter [28].
Therefore, we examined the promoter activity of this 0.6-
kb fragment in human pancreatic cancer cells by using the
dual luciferase reporter assay. We showed that the relative
luciferase activity in AsPC-1, PANC-1, and Suit-2 cells was
greater than that in midkne-negative MIAPaCa-2 cells.
Transcriptional activity in the cell lines was generally par-
allel to the level of midkne expression. In CFPAC-1 cells,
however, the level of midkne expression did not corre-
spond well with the transcripitional activity of the midkne
promoter. We cannot explain this discrepancy, but it has
been reported that the level of endogenous midkne
expression and its promoter activity are not always corre-
lated with each other because of various factors such as
negative and positive regulatory elements residing outside
the region analysed [29]. Another possible explanation
may be differences between cell lines with respect to regu-
lation of the proteins involved in transcription [29].
Because the efficiency of adenoviral transfection varies
between cell lines, it was essential to examine the infectiv-
ity of Ad5GFP for multiple human pancreatic cancer cell
lines. Adenoviral transduction efficiency was far lower for
AsPC-1 than the other cell lines. Adenoviral replication in
AsPC-1 cells was lower than in any other midkine-positive
cell line and no killing of AsPC-1 cells was observed at 10
MOI, although these cells showed high midkine expres-
sion and transcriptional activity. Thus, we consider that
adenoviral transduction efficiency as well as transcrip-
tional activity is critical for adenovirus-mediated gene
therapy. In pancreatic cancer cells, the combined effi-
ciency of transduction and transcription determines the
actual cell-killing effect of Ad5MK.
When clinical application is considered, not only anti-
tumor activity but also toxicity for normal tissues should
be taken into account. In this regard, Ad5MK showed spe-
cific cytotoxicity for midkine-positive cells both in vitro
and in vivo. Despite the target selectivity of Ad5MK, weak
E1A expression was found in midkine-negative cells after
infection with 5 MOI of Ad5MK. Type 5 adenoviruses are
commonly used in viral therapy experiments, but show
Anti-tumor effect of Ad5MK in a Suit-2 intraperitoneal xenograft model Figure 6
Anti-tumor effect of Ad5MK in a Suit-2 intraperitoneal xenograft model. After intraperitoneal inoculation of 2 × 
106/ml Suit-2 cells in nude mice, 2 × 109 PFU of Ad5GFP or Ad5MK, or 500 μl of PBS, was administered intraperitoneally. 
There was a significant difference of survival time between the Ad5MK group and the other groups (p = 0.0002 Log-rank test 
and p = 0.0002 by Wilcoxson's test).Journal of Experimental & Clinical Cancer Research 2008, 27:30 http://www.jeccr.com/content/27/1/30
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species-specific replication, and it has been reported that
these adenoviruses do not replicate in mice or rats. There
are no suitable animal models apart from the cotton rat to
assess the toxicity of conditionally replicative adenovi-
ruses, but replicative viruses have already shown at least
low-level viral production and/or systemic toxicity in clin-
ical trials[25,30,31]. The precise requirements for selective
targeting to prevent damage to normal tissues in vivo need
to be clarified in the future.
We demonstrated an anti-tumor effect of Ad5MK on mid-
kine-positive tumor cells in vivo as well as in vitro. Our ani-
mal studies showed that mice treated with Ad5MK
survived for significantly longer than the other groups.
Even in the Ad5MK group, however, half of the mice died
due to peritoneal dissemination after about 50 days. This
may have been due to an inadequate dose of adenovirus
or because of the regrowth of cancer cells with resistance
to adenovirus-mediated gene therapy. In this study, we
only gave a single dose of adenovirus intraperitoneally
after tumor cell inoculation. In the future, we should
investigate the optimum volume and number of adenovi-
rus doses to improve the efficacy of Ad5MK treatment.
Another way to improve the results could be employment
of fiber-modified adenoviruses, which can enter cancer
cells resistant to conventional adenoviral gene transfer in
a coxsackievirus and adenovirus receptor (CAR)-inde-
pendent manner.
Conclusion
Midkine expression was increased in pancreatic cancer cell
lines and pancreatic cancer tissues. Ad5MK showed spe-
cific targeting of and cytotoxicity for midkine-positive
cells both in vitro and in vivo. These results suggest that rep-
lication-competent adenoviruses based on the midkine
promoter might have the potential to be used in gene
therapy for pancreatic cancer.
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